Table 3.
List of KDM genes significantly up- or down-regulated in PCa clinical subtypes (MSKCC and Oncomine databases)
| Gene | Clinical Variable | Gene expression | P value | Putative function | Oncomine |
|---|---|---|---|---|---|
| KDM1B |
Overall Survival (OS) |
Higher predicts shorter OS |
0.0045 |
Oncogene |
In agreement |
| KDM2B |
PSA level at diagnosis |
Higher predicts higher PSA |
0.0070 |
Oncogene |
|
| |
Gleason Score |
Higher predicts higher grade |
0.0001 |
|
|
| |
Lymph Node invasion |
Higher predicts invasion |
0.0002 |
|
|
| |
Metastasis |
Higher predicts higher metastatic risk |
3.09E-07 |
|
|
| |
Recurrence-Free Survival (RFS) |
Higher predicts shorter RFS |
0.0066 |
|
|
| KDM3B |
PSA level at diagnosis |
Lower predicts higher PSA |
0.0004 |
Oncosuppressor |
In disagreement |
| |
Gleason Score |
Lower predicts higher grade |
0.0066 |
|
|
| KDM4C |
Metastasis |
Lower in non-metastatic tumors |
0.0086 |
Oncogene |
In agreement |
| KDM4D |
Gleason Score |
Higher predicts higher grade |
0.0002 |
Oncogene |
|
| |
Lymph Node invasion |
Higher predicts invasion |
0.0019 |
|
|
| |
Recurrence-Free Survival (RFS) |
Higher predicts shorter RFS |
0.0002 |
|
|
| |
Metastasis |
Lower in non-metastatic tumors |
0.001 |
|
|
| KDM5A |
Probability of recurrence after prostatectomy |
Higher predicts higher probability |
0.002 |
Oncogene |
|
| KDM5D |
Gleason Score |
Higher predicts lower grade |
0.0035 |
Oncosuppressor |
In agreement |
| |
Lymph Node invasion |
Lower predict invasion |
0.0036 |
|
|
| |
Metastasis |
Lower predicts higher metastatic risk |
3.7E-5 |
|
|
| |
Probability of recurrence after prostatectomy |
Lower predicts higher probability |
0.0003 |
|
|
| KDM7 |
Gleason Score |
Higher predicts higher grade |
0.0016 |
? |
|
| |
Lymph Node invasion |
Lower predicts invasion |
0.0009 |
|
|
| Recurrence-Free Survival (RFS) | Higher predicts longer RFS | 0.008 |
From the MSKCC database, we report all associations with p < 0.01, for the following clinical variables: PSA (prostate specific antigen) levels at diagnosis; Gleason score, based on prostatectomy; lymph node invasion; metastatic risk; recurrence free survival (or probability of recurrence) after prostatectomy; overall survival. Oncomine data are described as “in agreement” if they confirm the oncogene/oncosuppressor function deduced from the MSKCC database. Oncomine thresholds: p < 0.01; fold-change >2.0. Oncomine data are shown in Figure 2. For gene aliases, see Table 1.